FOXO4-DRI
Evidence: CMitochondrial / Cellular Aging
Evidence Snapshot
What this grade covers
A for experimental identity; B for selected cell and mouse findings; D/E for human efficacy, safety, approval, anti-aging, longevity, endocrine, or dosing claims.
Regulatory Context
FOXO4-DRI is not FDA approved. No registered human interventional study was identified in the reviewed ClinicalTrials.gov search. Absence from a specific FDA compounding list does not establish approval or compounding eligibility.
Research Takeaway
FOXO4-DRI is a D-retro-inverso peptide engineered to disrupt the FOXO4-p53 interaction in senescent cells and is not the FOXO4 protein itself.
Evidence boundary: A senolytic mechanism in experimental systems does not establish selective elimination of senescent cells in humans.
See all 6 evidence claims →Quick Summary
FOXO4-DRI is an experimental D-retro-inverso peptide designed to disrupt the FOXO4-p53 interaction in senescent cells. Cell and mouse studies show senolytic activity in selected models, but no human therapeutic or safety evidence has been established.
Mechanism & Research Overview
FOXO4-DRI is an experimental D-retro-inverso peptide designed to interfere with the protein-protein interaction between the transcription factor FOXO4 and the tumor suppressor p53. The original construct includes a cell-penetrating sequence to facilitate intracellular delivery. "DRI" refers to a retro-inverso design using D-amino acids in reversed sequence order to preserve aspects of side-chain topology while increasing resistance to proteolytic degradation.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
FOXO4-DRI is a D-retro-inverso peptide engineered to disrupt the FOXO4-p53 interaction in senescent cells and is not the FOXO4 protein itself.
Does not establish
Evidence boundary: A senolytic mechanism in experimental systems does not establish selective elimination of senescent cells in humans.
Supported
In mouse models, FOXO4-DRI induced apoptosis of senescent cells and improved selected measures of tissue homeostasis, fitness, fur density, and renal function.
Does not establish
Evidence boundary: Mouse rejuvenation phenotypes do not establish human anti-aging efficacy.
Supported
No FDA-approved FOXO4-DRI drug product was identified in the Drugs@FDA search performed for this frozen package.
Does not establish
Evidence boundary: This does not preclude future clinical development after the research date.
Supported
The cited evidence does not establish a human adverse-event profile, therapeutic window, pharmacokinetics, or long-term safety margin for FOXO4-DRI.
Does not establish
Evidence boundary: Preclinical selectivity is not proof of clinical safety.
Supported
No controlled human therapeutic trial is included in this package that establishes FOXO4-DRI as a longevity, rejuvenation, renal, or anti-aging treatment.
Does not establish
Evidence boundary: The term senolytic should not be converted into a claim of proven lifespan extension in humans.
Supported
Any study exposure presented on the site must be labeled Preclinical Study Dosing; human dose conversion and consumer dosing recommendations are prohibited.
Does not establish
Evidence boundary: Animal exposure cannot be scaled into a human-use protocol.
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
p53 is a central regulator of DNA-damage responses, apoptosis, senescence, genomic stability, and tumor suppression. Disruption of FOXO4-p53 signaling may have context-dependent effects outside the intended senescent-cell population.Higher-Priority Safety Consideration
Unknown hepatic, renal, cardiovascular, neurologic, reproductive, and immune effects; unknown pregnancy and developmental risks; unknown consequences of repeated senolytic cycles; and absence of validated human biomarkers for safe target engagement. Limited mouse tolerability findings cannot establish human safety.Safety Consideration
Senescent cells are heterogeneous and can have beneficial roles in wound healing, embryogenesis, tissue repair, and tumor suppression. Off-target apoptosis or depletion of beneficial senescent cells is a possible risk.Safety Consideration
Biodistribution and tissue penetration are unknown, as is the interaction with tumors carrying wild-type or mutant p53.Safety Consideration
Immunogenicity and anti-drug antibodies, aggregation, peptide impurities, endotoxins, and sterility are unaddressed by the current evidence base.
Research Areas Being Studied
Research areas discussed on this page reflect the Mitochondrial / Cellular Aging category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| FOXO4-DRI Induces Keloid Senescent Fibroblast Apoptosis | 2025 | Evaluated FOXO4-DRI in keloid-derived senescent fibroblasts. Supports experimental senescence biology but does not establish clinical treatment of keloids or wound healing. | |||
| The Disordered p53 Transactivation Domain Is the Target of FOXO4 and FOXO4-DRI | 2025 | Recent structural work further characterized the interaction of FOXO4 and FOXO4-DRI with the disordered p53 transactivation domain. Mechanistic clarification does not establish therapeutic selectivity or human safety. | |||
| FOXO4 Peptide in Pulmonary Fibrosis Model | Evaluated FOXO4-DRI in a bleomycin-induced pulmonary-fibrosis model. Supports experimental senescence biology but does not establish clinical treatment of pulmonary fibrosis. | ||||
| FOXO4-DRI and Age-Related Testosterone Secretion in Mice | Mouse and cell studies reported reduced senescent Leydig-cell burden, improved testicular microenvironment, and partial restoration of age-related testosterone secretion in mice. These findings do not establish treatment of human hypogonadism, infertility, low testosterone, erectile dysfunction, or age-related reproductive decline. | ||||
| FOXO4-DRI and Spermatogenesis in Aged Mice | Reported improved sperm quality and spermatogenesis in aged mice. These findings do not establish treatment of human infertility or age-related reproductive decline. | ||||
| FOXO4-DRI and Vascular Aging in Mice | Evaluated FOXO4-DRI in senescent vascular-endothelial cells and aged mice. Supports experimental senescence biology but does not establish clinical treatment of cardiovascular aging. | ||||
| FOXO4-DRI in Expanded Human Chondrocytes | Evaluated FOXO4-DRI in expanded human chondrocytes in vitro. Supports experimental senescence biology but does not establish clinical treatment of arthritis or joint disease. | ||||
| Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging | The 2017 Cell study identified FOXO4 as a regulator of senescent-cell viability and developed FOXO4-DRI to compete with FOXO4-p53 binding. In cultured senescent cells, the peptide promoted p53 redistribution and apoptosis. In progeroid and naturally aged mice, treatment was associated with improvements in selected measures including activity, fur density, and renal-function markers. These results were preclinical and did not demonstrate increased human lifespan, reversal of human aging, or clinical safety. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| Drugs@FDA: FDA-Approved Drugs Database | 2026 | Current Drugs@FDA name searches performed for this frozen package did not identify approved drug products under the names AHK-Cu, FOXO4-DRI, Pinealon, or Mechano Growth Factor. A negative name search does not exclude differently named products but establishes that no approval was identified under these research names. | |||
| ClinicalTrials.gov Search Portal | No registered human interventional trial of FOXO4-DRI or Crystagen was identified in the reviewed ClinicalTrials.gov searches. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
FOXO4-DRI targets signaling involving p53, a central tumor-suppressor and cell-fate regulator. Human biodistribution, selectivity, immunogenicity, off-target apoptosis, chronic toxicity, reproductive effects, and cancer-related risks remain unknown. No FDA-approved or clinically validated human dosing regimen exists; nothing on this page is medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-07-30.
Follow research updates for FOXO4-DRI
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.